Camptothecin (
CPT), a
quinoline alkaloid isolated from Camptotheca acuminate, targets
topoisomerase I, which is continuously expressed in
cancer cells. However, the molecular mechanisms responsible for
CPT-induced
telomerase inhibition remain unclear. Unexpectedly, we found that
CPT upregulates hTERT expression and concomitantly increases
telomerase activity. However, transfection of hTERT-targeting
siRNA had no effect on
CPT-induced G2/M phase arrest, suggesting that
CPT-induced
telomerase activation was not related to G2/M phase arrest.
CPT simultaneously increased Nrf2 expression and the level of intracellular
reactive oxygen species (ROS), whereas pretreatment with the
antioxidants N-acetyl-
cysteine (NAC) or
glutathione (GSH) strongly attenuated ROS production, which was accompanied by hTERT downregulation. Additionally, transient Nrf2 knockdown enhanced
CPT-induced ROS production and hTERT promoter activity.
CPT also upregulated hTERT expression and
telomerase activity by inducing c-Myc and Sp1 expression and activity. Moreover, c-Myc stimulated ROS production in response to
CPT, leading to Sp1 activation, which promoted hTERT expression and
telomerase activity.
CPT treatment enhanced the phosphorylation of PI3K and Akt, which led to hTERT phosphorylation into the nucleus. These findings demonstrate that
CPT positively regulates
telomerase activity by upregulating hTERT expression and phosphorylation via the c-Myc/ROS/Sp1 and PI3K/Akt axis.